NEWS

Shanghai, April 25th, 2021. Linno (Shanghai) Pharmaceuticals Inc. (Linno) has officially moved into its newly renovated Shanghai R&D center. The new R&D center is located in the Zhangjiang Science and Technology Innovation Park, Pudong New District of Shanghai City, with approximately 9,000 square feet of laboratory and office space.

Linno was founded in the “Pharmaceutical Valley” of Zhangjiang, Shanghai in August of 2019. Commited to developing novel platform technologies to address major challenges in the development of protein-based therapeutics, Linno has invested in creating novel technologies of crossing blood-brain barrier, optimizing half-life profile and others. The outcomes of Linno’s rigorous R&D in healthcare solutions would enable biologics with superior pharmaceutical properties such as targeted delivery to disease site, extended circulating half-life, more convenient dosing route, or reduced manufacturing cost, to serve the patients suffering from severe and chronic diseases.

Since its inception one year ago, the research team at Linno has made remarkable progress in developing technical platforms. Their R&D breakthroughs center around drug delivery across the blood-brain barrier and establishing scientific bases and technical capabilities, including expertise in complement biology and rare diseases and in-house capabilities from antibody discovery to preclinical proof-of-concept studies. Multiple therapeutics R&D programs at Linno have been in stages of preclinical proof-of-concept and candidate nomination.

Moving into the state-of-art R&D center will enable Linno to expand its growing capabilities and capacities in molecule discovery, protein science, cell biology, and preclinical sciences. The expanded lab and office spaces also facilitate Linno’s effort to establish technical capabilities in analytical sciences and process development or CMC, that would combinedly ensure time- and cost-efficient R&D activities for the expanding R&D programs and planned IND submissions.